ADTX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Aditxt Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerADTX

Market Cap0.1M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Aditxt Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Laboratory assessment of antibody profiles in COVID-19 using Antibody.

Pipeline

Asset	Indication	Modality	Stage	Public Note
Laboratory assessment of antibody profiles	COVID-19	Antibody	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05379478	n/a	COMPLETED	403	2023-12-01

Scientific Context

literature_publication | Correction: Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals.
literature_publication | Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals.
asset_name | Laboratory assessment of antibody profiles
asset_name | Laboratory assessment of antibody profiles
asset_name | Laboratory assessment of antibody profiles

Want the full ADTX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.